Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Long-Term Debt Repayments (2016 - 2025)

Vistagen Therapeutics' Long-Term Debt Repayments history spans 13 years, with the latest figure at $278000.0 for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments changed N/A year-over-year to $278000.0; the TTM value through Dec 2025 reached $642000.0, changed N/A, while the annual FY2024 figure was $985000.0, 4.74% down from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $278000.0 at Vistagen Therapeutics, up from $274000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $278000.0 in Q4 2025 and bottomed at -$1000.0 in Q4 2023.
  • The 3-year median for Long-Term Debt Repayments is $149750.0 (2021), against an average of $156750.0.
  • The largest YoY upside for Long-Term Debt Repayments was 28.59% in 2021 against a maximum downside of 28.59% in 2021.
  • A 3-year view of Long-Term Debt Repayments shows it stood at $98500.0 in 2021, then plummeted by 101.02% to -$1000.0 in 2023, then soared by 27900.0% to $278000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Long-Term Debt Repayments are $278000.0 (Q4 2025), $274000.0 (Q3 2025), and $90000.0 (Q2 2025).